Bioengineered Protein Drugs-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data
Report Summary
Bioengineered Protein Drugs-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Bioengineered Protein Drugs industry, standing on the readers’ perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Top 20 Countries Market Size of Bioengineered Protein Drugs 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Bioengineered Protein Drugs worldwide and market share by regions, with company and product introduction, position in the Bioengineered Protein Drugs market
Market status and development trend of Bioengineered Protein Drugs by types and applications
Cost and profit status of Bioengineered Protein Drugs, and marketing status
Market growth drivers and challenges
The report segments the global Bioengineered Protein Drugs market as:
Global Bioengineered Protein Drugs Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)
Asia Pacific (China, Japan, India, Southeast Asia and Australia)
Latin America (Brazil, Argentina and Colombia)
Middle East and Africa
Global Bioengineered Protein Drugs Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Therapeutic Proteins
Monoclonal Antibodies
Vaccines
Global Bioengineered Protein Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Diabetes and Hormonal Disorders
Genetic and Fertility Disorders
Cancers
Organ Transplants
Others
Global Bioengineered Protein Drugs Market: Manufacturers Segment Analysis (Company and Product introduction, Bioengineered Protein Drugs Sales Volume, Revenue, Price and Gross Margin):
Abbott Laboratories
F. Hoffmann-La Roche Ltd
Amgen, Inc.
Bayer AG
Merck & Co., Inc.
Dr. Reddy's Laboratories Ltd.
Biocon Ltd.
Eli Lilly and Company
Sanofi
GlaxoSmithKline plc
Johnson & Johnson
JanssenNovartis AG
Panacea Biotec
ProBioGen AG
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Bioengineered Protein Drugs-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Bioengineered Protein Drugs industry, standing on the readers’ perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Top 20 Countries Market Size of Bioengineered Protein Drugs 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Bioengineered Protein Drugs worldwide and market share by regions, with company and product introduction, position in the Bioengineered Protein Drugs market
Market status and development trend of Bioengineered Protein Drugs by types and applications
Cost and profit status of Bioengineered Protein Drugs, and marketing status
Market growth drivers and challenges
The report segments the global Bioengineered Protein Drugs market as:
Global Bioengineered Protein Drugs Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)
Asia Pacific (China, Japan, India, Southeast Asia and Australia)
Latin America (Brazil, Argentina and Colombia)
Middle East and Africa
Global Bioengineered Protein Drugs Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Therapeutic Proteins
Monoclonal Antibodies
Vaccines
Global Bioengineered Protein Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Diabetes and Hormonal Disorders
Genetic and Fertility Disorders
Cancers
Organ Transplants
Others
Global Bioengineered Protein Drugs Market: Manufacturers Segment Analysis (Company and Product introduction, Bioengineered Protein Drugs Sales Volume, Revenue, Price and Gross Margin):
Abbott Laboratories
F. Hoffmann-La Roche Ltd
Amgen, Inc.
Bayer AG
Merck & Co., Inc.
Dr. Reddy's Laboratories Ltd.
Biocon Ltd.
Eli Lilly and Company
Sanofi
GlaxoSmithKline plc
Johnson & Johnson
JanssenNovartis AG
Panacea Biotec
ProBioGen AG
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF BIOENGINEERED PROTEIN DRUGS
1.1 Definition of Bioengineered Protein Drugs in This Report
1.2 Commercial Types of Bioengineered Protein Drugs
1.2.1 Therapeutic Proteins
1.2.2 Monoclonal Antibodies
1.2.3 Vaccines
1.3 Downstream Application of Bioengineered Protein Drugs
1.3.1 Diabetes and Hormonal Disorders
1.3.2 Genetic and Fertility Disorders
1.3.3 Cancers
1.3.4 Organ Transplants
1.3.5 Others
1.4 Development History of Bioengineered Protein Drugs
1.5 Market Status and Trend of Bioengineered Protein Drugs 2013-2023
1.5.1 Global Bioengineered Protein Drugs Market Status and Trend 2013-2023
1.5.2 Regional Bioengineered Protein Drugs Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Bioengineered Protein Drugs 2013-2017
2.2 Sales Market of Bioengineered Protein Drugs by Regions
2.2.1 Sales Volume of Bioengineered Protein Drugs by Regions
2.2.2 Sales Value of Bioengineered Protein Drugs by Regions
2.3 Production Market of Bioengineered Protein Drugs by Regions
2.4 Global Market Forecast of Bioengineered Protein Drugs 2018-2023
2.4.1 Global Market Forecast of Bioengineered Protein Drugs 2018-2023
2.4.2 Market Forecast of Bioengineered Protein Drugs by Regions 2018-2023
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Bioengineered Protein Drugs by Types
3.2 Sales Value of Bioengineered Protein Drugs by Types
3.3 Market Forecast of Bioengineered Protein Drugs by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Bioengineered Protein Drugs by Downstream Industry
4.2 Global Market Forecast of Bioengineered Protein Drugs by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Bioengineered Protein Drugs Market Status by Countries
5.1.1 North America Bioengineered Protein Drugs Sales by Countries (2013-2017)
5.1.2 North America Bioengineered Protein Drugs Revenue by Countries (2013-2017)
5.1.3 United States Bioengineered Protein Drugs Market Status (2013-2017)
5.1.4 Canada Bioengineered Protein Drugs Market Status (2013-2017)
5.1.5 Mexico Bioengineered Protein Drugs Market Status (2013-2017)
5.2 North America Bioengineered Protein Drugs Market Status by Manufacturers
5.3 North America Bioengineered Protein Drugs Market Status by Type (2013-2017)
5.3.1 North America Bioengineered Protein Drugs Sales by Type (2013-2017)
5.3.2 North America Bioengineered Protein Drugs Revenue by Type (2013-2017)
5.4 North America Bioengineered Protein Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Bioengineered Protein Drugs Market Status by Countries
6.1.1 Europe Bioengineered Protein Drugs Sales by Countries (2013-2017)
6.1.2 Europe Bioengineered Protein Drugs Revenue by Countries (2013-2017)
6.1.3 Germany Bioengineered Protein Drugs Market Status (2013-2017)
6.1.4 UK Bioengineered Protein Drugs Market Status (2013-2017)
6.1.5 France Bioengineered Protein Drugs Market Status (2013-2017)
6.1.6 Italy Bioengineered Protein Drugs Market Status (2013-2017)
6.1.7 Russia Bioengineered Protein Drugs Market Status (2013-2017)
6.1.8 Spain Bioengineered Protein Drugs Market Status (2013-2017)
6.1.9 Benelux Bioengineered Protein Drugs Market Status (2013-2017)
6.2 Europe Bioengineered Protein Drugs Market Status by Manufacturers
6.3 Europe Bioengineered Protein Drugs Market Status by Type (2013-2017)
6.3.1 Europe Bioengineered Protein Drugs Sales by Type (2013-2017)
6.3.2 Europe Bioengineered Protein Drugs Revenue by Type (2013-2017)
6.4 Europe Bioengineered Protein Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Bioengineered Protein Drugs Market Status by Countries
7.1.1 Asia Pacific Bioengineered Protein Drugs Sales by Countries (2013-2017)
7.1.2 Asia Pacific Bioengineered Protein Drugs Revenue by Countries (2013-2017)
7.1.3 China Bioengineered Protein Drugs Market Status (2013-2017)
7.1.4 Japan Bioengineered Protein Drugs Market Status (2013-2017)
7.1.5 India Bioengineered Protein Drugs Market Status (2013-2017)
7.1.6 Southeast Asia Bioengineered Protein Drugs Market Status (2013-2017)
7.1.7 Australia Bioengineered Protein Drugs Market Status (2013-2017)
7.2 Asia Pacific Bioengineered Protein Drugs Market Status by Manufacturers
7.3 Asia Pacific Bioengineered Protein Drugs Market Status by Type (2013-2017)
7.3.1 Asia Pacific Bioengineered Protein Drugs Sales by Type (2013-2017)
7.3.2 Asia Pacific Bioengineered Protein Drugs Revenue by Type (2013-2017)
7.4 Asia Pacific Bioengineered Protein Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Bioengineered Protein Drugs Market Status by Countries
8.1.1 Latin America Bioengineered Protein Drugs Sales by Countries (2013-2017)
8.1.2 Latin America Bioengineered Protein Drugs Revenue by Countries (2013-2017)
8.1.3 Brazil Bioengineered Protein Drugs Market Status (2013-2017)
8.1.4 Argentina Bioengineered Protein Drugs Market Status (2013-2017)
8.1.5 Colombia Bioengineered Protein Drugs Market Status (2013-2017)
8.2 Latin America Bioengineered Protein Drugs Market Status by Manufacturers
8.3 Latin America Bioengineered Protein Drugs Market Status by Type (2013-2017)
8.3.1 Latin America Bioengineered Protein Drugs Sales by Type (2013-2017)
8.3.2 Latin America Bioengineered Protein Drugs Revenue by Type (2013-2017)
8.4 Latin America Bioengineered Protein Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Bioengineered Protein Drugs Market Status by Countries
9.1.1 Middle East and Africa Bioengineered Protein Drugs Sales by Countries (2013-2017)
9.1.2 Middle East and Africa Bioengineered Protein Drugs Revenue by Countries (2013-2017)
9.1.3 Middle East Bioengineered Protein Drugs Market Status (2013-2017)
9.1.4 Africa Bioengineered Protein Drugs Market Status (2013-2017)
9.2 Middle East and Africa Bioengineered Protein Drugs Market Status by Manufacturers
9.3 Middle East and Africa Bioengineered Protein Drugs Market Status by Type (2013-2017)
9.3.1 Middle East and Africa Bioengineered Protein Drugs Sales by Type (2013-2017)
9.3.2 Middle East and Africa Bioengineered Protein Drugs Revenue by Type (2013-2017)
9.4 Middle East and Africa Bioengineered Protein Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF BIOENGINEERED PROTEIN DRUGS
10.1 Global Economy Situation and Trend Overview
10.2 Bioengineered Protein Drugs Downstream Industry Situation and Trend Overview
CHAPTER 11 BIOENGINEERED PROTEIN DRUGS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Bioengineered Protein Drugs by Major Manufacturers
11.2 Production Value of Bioengineered Protein Drugs by Major Manufacturers
11.3 Basic Information of Bioengineered Protein Drugs by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Bioengineered Protein Drugs Major Manufacturer
11.3.2 Employees and Revenue Level of Bioengineered Protein Drugs Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 BIOENGINEERED PROTEIN DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 Abbott Laboratories
12.1.1 Company profile
12.1.2 Representative Bioengineered Protein Drugs Product
12.1.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Abbott Laboratories
12.2 F. Hoffmann-La Roche Ltd
12.2.1 Company profile
12.2.2 Representative Bioengineered Protein Drugs Product
12.2.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche Ltd
12.3 Amgen, Inc.
12.3.1 Company profile
12.3.2 Representative Bioengineered Protein Drugs Product
12.3.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Amgen, Inc.
12.4 Bayer AG
12.4.1 Company profile
12.4.2 Representative Bioengineered Protein Drugs Product
12.4.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Bayer AG
12.5 Merck & Co., Inc.
12.5.1 Company profile
12.5.2 Representative Bioengineered Protein Drugs Product
12.5.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Merck & Co., Inc.
12.6 Dr. Reddy's Laboratories Ltd.
12.6.1 Company profile
12.6.2 Representative Bioengineered Protein Drugs Product
12.6.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Dr. Reddy's Laboratories Ltd.
12.7 Biocon Ltd.
12.7.1 Company profile
12.7.2 Representative Bioengineered Protein Drugs Product
12.7.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Biocon Ltd.
12.8 Eli Lilly and Company
12.8.1 Company profile
12.8.2 Representative Bioengineered Protein Drugs Product
12.8.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Eli Lilly and Company
12.9 Sanofi
12.9.1 Company profile
12.9.2 Representative Bioengineered Protein Drugs Product
12.9.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Sanofi
12.10 GlaxoSmithKline plc
12.10.1 Company profile
12.10.2 Representative Bioengineered Protein Drugs Product
12.10.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline plc
12.11 Johnson & Johnson
12.11.1 Company profile
12.11.2 Representative Bioengineered Protein Drugs Product
12.11.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson
12.12 JanssenNovartis AG
12.12.1 Company profile
12.12.2 Representative Bioengineered Protein Drugs Product
12.12.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of JanssenNovartis AG
12.13 Panacea Biotec
12.13.1 Company profile
12.13.2 Representative Bioengineered Protein Drugs Product
12.13.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Panacea Biotec
12.14 ProBioGen AG
12.14.1 Company profile
12.14.2 Representative Bioengineered Protein Drugs Product
12.14.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of ProBioGen AG
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BIOENGINEERED PROTEIN DRUGS
13.1 Industry Chain of Bioengineered Protein Drugs
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF BIOENGINEERED PROTEIN DRUGS
14.1 Cost Structure Analysis of Bioengineered Protein Drugs
14.2 Raw Materials Cost Analysis of Bioengineered Protein Drugs
14.3 Labor Cost Analysis of Bioengineered Protein Drugs
14.4 Manufacturing Expenses Analysis of Bioengineered Protein Drugs
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
1.1 Definition of Bioengineered Protein Drugs in This Report
1.2 Commercial Types of Bioengineered Protein Drugs
1.2.1 Therapeutic Proteins
1.2.2 Monoclonal Antibodies
1.2.3 Vaccines
1.3 Downstream Application of Bioengineered Protein Drugs
1.3.1 Diabetes and Hormonal Disorders
1.3.2 Genetic and Fertility Disorders
1.3.3 Cancers
1.3.4 Organ Transplants
1.3.5 Others
1.4 Development History of Bioengineered Protein Drugs
1.5 Market Status and Trend of Bioengineered Protein Drugs 2013-2023
1.5.1 Global Bioengineered Protein Drugs Market Status and Trend 2013-2023
1.5.2 Regional Bioengineered Protein Drugs Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Bioengineered Protein Drugs 2013-2017
2.2 Sales Market of Bioengineered Protein Drugs by Regions
2.2.1 Sales Volume of Bioengineered Protein Drugs by Regions
2.2.2 Sales Value of Bioengineered Protein Drugs by Regions
2.3 Production Market of Bioengineered Protein Drugs by Regions
2.4 Global Market Forecast of Bioengineered Protein Drugs 2018-2023
2.4.1 Global Market Forecast of Bioengineered Protein Drugs 2018-2023
2.4.2 Market Forecast of Bioengineered Protein Drugs by Regions 2018-2023
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Bioengineered Protein Drugs by Types
3.2 Sales Value of Bioengineered Protein Drugs by Types
3.3 Market Forecast of Bioengineered Protein Drugs by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Bioengineered Protein Drugs by Downstream Industry
4.2 Global Market Forecast of Bioengineered Protein Drugs by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Bioengineered Protein Drugs Market Status by Countries
5.1.1 North America Bioengineered Protein Drugs Sales by Countries (2013-2017)
5.1.2 North America Bioengineered Protein Drugs Revenue by Countries (2013-2017)
5.1.3 United States Bioengineered Protein Drugs Market Status (2013-2017)
5.1.4 Canada Bioengineered Protein Drugs Market Status (2013-2017)
5.1.5 Mexico Bioengineered Protein Drugs Market Status (2013-2017)
5.2 North America Bioengineered Protein Drugs Market Status by Manufacturers
5.3 North America Bioengineered Protein Drugs Market Status by Type (2013-2017)
5.3.1 North America Bioengineered Protein Drugs Sales by Type (2013-2017)
5.3.2 North America Bioengineered Protein Drugs Revenue by Type (2013-2017)
5.4 North America Bioengineered Protein Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Bioengineered Protein Drugs Market Status by Countries
6.1.1 Europe Bioengineered Protein Drugs Sales by Countries (2013-2017)
6.1.2 Europe Bioengineered Protein Drugs Revenue by Countries (2013-2017)
6.1.3 Germany Bioengineered Protein Drugs Market Status (2013-2017)
6.1.4 UK Bioengineered Protein Drugs Market Status (2013-2017)
6.1.5 France Bioengineered Protein Drugs Market Status (2013-2017)
6.1.6 Italy Bioengineered Protein Drugs Market Status (2013-2017)
6.1.7 Russia Bioengineered Protein Drugs Market Status (2013-2017)
6.1.8 Spain Bioengineered Protein Drugs Market Status (2013-2017)
6.1.9 Benelux Bioengineered Protein Drugs Market Status (2013-2017)
6.2 Europe Bioengineered Protein Drugs Market Status by Manufacturers
6.3 Europe Bioengineered Protein Drugs Market Status by Type (2013-2017)
6.3.1 Europe Bioengineered Protein Drugs Sales by Type (2013-2017)
6.3.2 Europe Bioengineered Protein Drugs Revenue by Type (2013-2017)
6.4 Europe Bioengineered Protein Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Bioengineered Protein Drugs Market Status by Countries
7.1.1 Asia Pacific Bioengineered Protein Drugs Sales by Countries (2013-2017)
7.1.2 Asia Pacific Bioengineered Protein Drugs Revenue by Countries (2013-2017)
7.1.3 China Bioengineered Protein Drugs Market Status (2013-2017)
7.1.4 Japan Bioengineered Protein Drugs Market Status (2013-2017)
7.1.5 India Bioengineered Protein Drugs Market Status (2013-2017)
7.1.6 Southeast Asia Bioengineered Protein Drugs Market Status (2013-2017)
7.1.7 Australia Bioengineered Protein Drugs Market Status (2013-2017)
7.2 Asia Pacific Bioengineered Protein Drugs Market Status by Manufacturers
7.3 Asia Pacific Bioengineered Protein Drugs Market Status by Type (2013-2017)
7.3.1 Asia Pacific Bioengineered Protein Drugs Sales by Type (2013-2017)
7.3.2 Asia Pacific Bioengineered Protein Drugs Revenue by Type (2013-2017)
7.4 Asia Pacific Bioengineered Protein Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Bioengineered Protein Drugs Market Status by Countries
8.1.1 Latin America Bioengineered Protein Drugs Sales by Countries (2013-2017)
8.1.2 Latin America Bioengineered Protein Drugs Revenue by Countries (2013-2017)
8.1.3 Brazil Bioengineered Protein Drugs Market Status (2013-2017)
8.1.4 Argentina Bioengineered Protein Drugs Market Status (2013-2017)
8.1.5 Colombia Bioengineered Protein Drugs Market Status (2013-2017)
8.2 Latin America Bioengineered Protein Drugs Market Status by Manufacturers
8.3 Latin America Bioengineered Protein Drugs Market Status by Type (2013-2017)
8.3.1 Latin America Bioengineered Protein Drugs Sales by Type (2013-2017)
8.3.2 Latin America Bioengineered Protein Drugs Revenue by Type (2013-2017)
8.4 Latin America Bioengineered Protein Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Bioengineered Protein Drugs Market Status by Countries
9.1.1 Middle East and Africa Bioengineered Protein Drugs Sales by Countries (2013-2017)
9.1.2 Middle East and Africa Bioengineered Protein Drugs Revenue by Countries (2013-2017)
9.1.3 Middle East Bioengineered Protein Drugs Market Status (2013-2017)
9.1.4 Africa Bioengineered Protein Drugs Market Status (2013-2017)
9.2 Middle East and Africa Bioengineered Protein Drugs Market Status by Manufacturers
9.3 Middle East and Africa Bioengineered Protein Drugs Market Status by Type (2013-2017)
9.3.1 Middle East and Africa Bioengineered Protein Drugs Sales by Type (2013-2017)
9.3.2 Middle East and Africa Bioengineered Protein Drugs Revenue by Type (2013-2017)
9.4 Middle East and Africa Bioengineered Protein Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF BIOENGINEERED PROTEIN DRUGS
10.1 Global Economy Situation and Trend Overview
10.2 Bioengineered Protein Drugs Downstream Industry Situation and Trend Overview
CHAPTER 11 BIOENGINEERED PROTEIN DRUGS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Bioengineered Protein Drugs by Major Manufacturers
11.2 Production Value of Bioengineered Protein Drugs by Major Manufacturers
11.3 Basic Information of Bioengineered Protein Drugs by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Bioengineered Protein Drugs Major Manufacturer
11.3.2 Employees and Revenue Level of Bioengineered Protein Drugs Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 BIOENGINEERED PROTEIN DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 Abbott Laboratories
12.1.1 Company profile
12.1.2 Representative Bioengineered Protein Drugs Product
12.1.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Abbott Laboratories
12.2 F. Hoffmann-La Roche Ltd
12.2.1 Company profile
12.2.2 Representative Bioengineered Protein Drugs Product
12.2.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche Ltd
12.3 Amgen, Inc.
12.3.1 Company profile
12.3.2 Representative Bioengineered Protein Drugs Product
12.3.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Amgen, Inc.
12.4 Bayer AG
12.4.1 Company profile
12.4.2 Representative Bioengineered Protein Drugs Product
12.4.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Bayer AG
12.5 Merck & Co., Inc.
12.5.1 Company profile
12.5.2 Representative Bioengineered Protein Drugs Product
12.5.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Merck & Co., Inc.
12.6 Dr. Reddy's Laboratories Ltd.
12.6.1 Company profile
12.6.2 Representative Bioengineered Protein Drugs Product
12.6.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Dr. Reddy's Laboratories Ltd.
12.7 Biocon Ltd.
12.7.1 Company profile
12.7.2 Representative Bioengineered Protein Drugs Product
12.7.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Biocon Ltd.
12.8 Eli Lilly and Company
12.8.1 Company profile
12.8.2 Representative Bioengineered Protein Drugs Product
12.8.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Eli Lilly and Company
12.9 Sanofi
12.9.1 Company profile
12.9.2 Representative Bioengineered Protein Drugs Product
12.9.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Sanofi
12.10 GlaxoSmithKline plc
12.10.1 Company profile
12.10.2 Representative Bioengineered Protein Drugs Product
12.10.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline plc
12.11 Johnson & Johnson
12.11.1 Company profile
12.11.2 Representative Bioengineered Protein Drugs Product
12.11.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson
12.12 JanssenNovartis AG
12.12.1 Company profile
12.12.2 Representative Bioengineered Protein Drugs Product
12.12.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of JanssenNovartis AG
12.13 Panacea Biotec
12.13.1 Company profile
12.13.2 Representative Bioengineered Protein Drugs Product
12.13.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Panacea Biotec
12.14 ProBioGen AG
12.14.1 Company profile
12.14.2 Representative Bioengineered Protein Drugs Product
12.14.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of ProBioGen AG
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BIOENGINEERED PROTEIN DRUGS
13.1 Industry Chain of Bioengineered Protein Drugs
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF BIOENGINEERED PROTEIN DRUGS
14.1 Cost Structure Analysis of Bioengineered Protein Drugs
14.2 Raw Materials Cost Analysis of Bioengineered Protein Drugs
14.3 Labor Cost Analysis of Bioengineered Protein Drugs
14.4 Manufacturing Expenses Analysis of Bioengineered Protein Drugs
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
